Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 for Idiopathic CD4 Lymphopenia
NCT05600920Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efineptakin alfa in idiopathic CD4 lymphocytopenia (ICL), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Adverse Events at 60 weeks. Started Nov 2024; status: recruiting.
02
Drugs
efineptakin alfa
03
Conditions
idiopathic CD4 lymphocytopenia (ICL)
Beyond the preview
Go deeper on NCT05600920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600920.